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This editorial refers to ‘Cardiomyocyte proliferation and
protection against post-myocardial infarction heart
failure by cyclin D1 and Skp2 ubiquitin ligase’ by
Tamamori-Adachi et al.,11 pp. 181–190, this issue.
A fundamental tenet in cardiac biology, namely that the heart
is a postmitotic organ incapable of regeneration, has recently
been challenged. According to the traditional belief, the
number of cardiac myocytes we are born with is all we will
have for the rest of our lives. If myocytes die (e.g. as the
result of infarction), they cannot be renewed. This is why
myocardial infarction (MI) and its consequences, such as con-
gestive heart failure, continue to be a major cause of death
worldwide despite the considerable therapeutic advances
that have been made over the past decades.
In one attempt to evade this dilemma, cell replacement
strategies are currently being investigated for their thera-
peutic potential to restore cardiac function. Indeed, a
growing body of evidence from both basic animal studies
and clinical trials indicates that cell-based strategies using
different stem cell populations such as embryonic stem
cells, skeletal myoblasts, haematopoietic stem cells, endo-
thelial progenitor cells, and mesenchymal stem cells might
be promising.1,2 According to these studies, improvements
in clinical symptoms, left-ventricular function, and myocar-
dial perfusion are feasible with cell therapy. However, there
is an ongoing controversy about the underlying mechanisms
and, particularly, the capability of the different implanted
progenitor cells to transdifferentiate and what the essential
prerequisites for this transdifferentiation might be. Only on
understanding these mechanisms and, likely, through the
appropriate priming and engineering of the cells to be
implanted regeneration by this approach might be achieved.
Another approach to induce cardiac regeneration for
repair after injury would be to reverse the terminal differ-
entiation, as many mammalian tissues respond to injury by
activating committed progenitor cells or by triggering pro-
liferation of differentiated cells that re-enter cell cycle.
Although several groups have described the presence of pro-
genitor or stem cells that can differentiate into cardiac myo-
cytes,3,4 there is still much debate and confusion in the ﬁeld
regarding their potential for cardiac myocyte differentiation
and myocardial repair.5,6 Limited induction of DNA synthesis
in the heart has been described in response to various
stimuli.7,8 Yet, there has been little evidence for cyto-
plasmic division or cytokinesis in mammals. In contrast to
cardiomyocytes from lower vertebrates, which are well
endowed to divide postnatally,9,10 proliferation ceases in
the perinatal mammalian heart in conjunction with the
downregulation of cyclin-dependent kinase (cdk) activities.
Myocytes undergo an additional round of DNA synthesis
and nuclear mitosis without cytokinesis (acytokinetic
mitosis) that leaves the majority of adult cardiac myocytes
binucleated in most species. Beyond this stage of differen-
tiation, further increases in cardiac mass are possible only
through an increase in cell size or hypertrophy.
The report by Tamamori-Adachi et al.11 in the current issue
of Cardiovascular Research provides encouraging evidence
that manipulation of positive and negative regulators of
cell cycle control mechanisms successfully promotes cardio-
myocyte division and, hence, might yield new strategies for
the treatment of ischaemic heart failure. The study con-
tinues previous work12 and shows that adenoviral delivery
of S-phase kinase-associated protein 2 (Skp2), an ubiquitin
ligase that mediates degradation of the cell cycle inhibitor
p27, together with nuclear-targeted cyclin D1 (D1NLS) and
Cdk4 results in increased proliferation (BrdU-positive cells
and expression of Ki67) and increased mitosis (phosphoryl-
ation of histone H3, Aurora B and Survivin) after coronary
artery ligation in rats. Furthermore, gene expression proﬁling
by microarray analysis of rat neonatal cardiomyocytes
expressing D1NLS and Cdk4 in culture showed gene activation
for a subset of G1/S, S phase, G2/M, and M phase check-
points, thereby further suggesting the feasibility of profound
and effectivemanipulation of cell cycle control in heart cells.
Indeed, the authors demonstrated cytokinesis in cardiomyo-
cytes in vivo with daughter cells staining positive for tropo-
myosin. To note, cytokinesis is important since in normal
adult hearts a number of cardiomyocytes are polyploid
and/or multinucleated. Moreover, nuclear hyperplasia and
multinucleation have been associated with cell hypertrophy
as mechanism of growth in the postnatal heart. The current
study complements the previous attempts to overcome the
proliferation arrest in adult cardiomyocytes by manipulation
of cell cycle control. In these earlier studies, transgenic mice
overexpressing cyclin D2 showed higher rates of DNA synthesis*
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and signs of mitosis (H3P) or newly formed myocardium after
infarction,13,14 likely by phosphorylation of cyclin D2-target
retinoblastoma gene product (pRb) being prevented. Accord-
ingly, a cyclin D2 knockout prevented the increase in the rela-
tive heart weight after transverse aortic constriction.15
Furthermore,mice lacking Rband p130 showed signs of persist-
ing proliferation of cardiomyocytes during adulthood (BrdU,
H3P), along with the expression of c-Myc, E2F, and CycE, and
increased activity of Cdk2, Cdk4, and Cdk6.16 There is also
strong evidence that inhibition of p38 MAPK in combination
with FGF1 stimulation, promotes hypertrophy and cytokinesis
in adult cardiomyocytes.17,18 Interestingly, inhibition of p38
MAPK augments growth factor-mediated induction of all
phases of the cell cycle and substantially enhances the prolif-
erative capacity of mammalian cardiomyocytes. Additionally,
p38 activity prevented upregulation of factors required for kar-
yokinesis and cytokinesis, suggesting a role for p38 in G2/M
checkpoint control. Furthermore, cyclin A2 induced cardio-
myocyte mitosis (H3P), increased myocardial proliferation,
and improved heart function after MI,19,20 while ectopic
expression of cyclin B1 and Cdk2 induced mitosis-promoting
factor (MPF) activity in adult cardiomyocytes, which resulted
in a mitotic phenotype, but no complete cell division.21
Taken together, the data in the current study further conﬁrm
that manipulation of cell cycle regulation might offer reason-
able strategies for cardiac regeneration and treatment of
ischaemic heart failure. The signiﬁcance of the induced
myocyte proliferation is strengthened by the observed protec-
tion against cardiac dysfunction and heart failure in an ischae-
mia/reperfusion-induced acute MI model.
There are, however, still unanswered questions that need
to be addressed. First, the quantitative contribution of the
observed myocyte proliferation per se to the observed pro-
tective effects is not clear. Besides technical limitations
(assessment and variability of the initial MI size), it is quite
possible that cardio-protective effects (i.e. smaller MI size
and improved function) are mediated by multiple mechan-
isms as stated by the authors. These may include paracrine
effects by induction or suppression of cytokines and growth
factors, resulting in reduced rate of apoptosis and increased
vascularization as also reported in this study. Also, the tem-
poral correlation of these angiogenic and anti-apoptic
effects to cell proliferation is not completely conclusive.
Moreover, the role of other factors contributing to post-
ischaemic heart failure (i.e. hypertrophy, remodelling) has
not been studied, and the occurrence of transient dedifferen-
tiation of the myoﬁbrils in the proliferating adult cardiomyo-
cytes has not been investigated. It may also be speculated
that the observed enhanced proliferation occurred in
young cardiomyocytes simply because the cells derive from
the (limited) pool of cardiac progenitor cells. If so, then
additional cell cycle regulators need to be targeted in
adult cardiomyocytes for a more substantial onset of
proliferation. Alternatively, this goal may also be achieved
by the development of more efﬁcient methods for gene deliv-
ery. Finally, the adenoviral delivery for gene transfer always
leaves the possibility of a somewhat dysregulated prolifer-
ation. As suggested by the authors, this potential problem
has to be considered in a clinical context. Alternative
methods like FGF1 stimulation/p38 MAPK inhibition, perios-
tin, or IGF1 are less speciﬁc but more easily adjustable.
Although the report by Tamamori-Adachi et al.11 empha-
sizes the rationale for continuing research on promoting
re-entry of myocytes into the cell cycle for cardiac regener-
ation, the fundamental shift in paradigm from the heart
being strictly a postmitotic organ to one that carries some,
although arrested, regenerative capacities clearly has a
long way to go before such a therapeutic strategy can be
applied in the clinical setting. In addition to taking into
account safety considerations, it will be a key prerequisite
to identify the appropriate master regulators of cell cycle
control or the most advantageous combinations thereof,
which was the aim of the current report.
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